Wockhardt (NSE:WOCKPHARMA) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
61 GF Score
Price ₹1,865.20
GF Value ₹1,246.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Wockhardt Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Wockhardt's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

NSE:WOCKPHARMA vs ZTS: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wockhardt Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Wockhardt's Margin of Safety % (DCF Dividends Based) falls into.


NSE:WOCKPHARMA
61GF Score
Wockhardt Ltd NSE:WOCKPHARMA
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,865.20 is trading 49.6% above its estimated GF Value™ of ₹1,246.45. GuruFocus considers Wockhardt to be Significantly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: ₹1,246.45 vs. price of ₹1,865.20 (49.6% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
61GF Score

Get the complete analysis for NSE:WOCKPHARMA

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,865.20
Price
₹1,246.45
GF Value